Septerna

Septerna is a California-based biopharmaceutical company specializing in the development of proteins that enhance the cellular uptake of therapeutic compounds. The company has recently gained attention for entering a significant collaboration with Novo Nordisk to develop oral medications for the treatment of obesity and diabetes, which could result in payments of up to $2.2 billion depending on the success of the partnership.